Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

Summary

A Multi-center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients with Gastric Ulcer

Timeline

Start

2022-09-19

Primary completion

2024-07-10

Completion

2024-07-19

Outcome

Met primary endpoint

paper An 8-week therapy involving zastaprazan 20 mg demonstrated noninferiority to lansoprazole 30 mg in the cumulative rate of healing of gastric ulcers at 8 weeks PMID 41540828 ↗

Publications

• Park KS, Kim HS, Oh JH, Chung WC, Choi SC, Lee SH, Kim TH, Cheung DY, Baik GH, Kim SM, Lee HL, Moon JS, Choi CW, Sohn C, Kim KO, Kim BW, Jung HK, Jung DH, Kim SS, Park MI, Lee JY, Kim GH, Moon HS, Chun H, Shim KN, Shin WG, Park CH, Kim T, Jung SW, Kim H, Jee SR, Lee K, Cho YK, Park SC, Cho J, Huh C, Kwon H, Kim J, Kim J, Park JJ. Randomized, Double-Blind, Active-Controlled, Parallel, Phase 3 Clinical Trial for Evaluating the Efficacy and Safety of Zastaprazan in Patients with Gastric Ulcers. Gut Liver. 2026 Jan 16. doi: 10.5009/gnl250334. Online ahead of print.

Drugs

Indications